Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Clinical Trials

Sertraline Vs. Placebo in the Treatment of Anxiety in Children and AdoLescents with NeurodevelopMental Disorders

Phase 2

Recruiting

Conditions: Tuberous Sclerosis
ADHD - Combined Type
Anxiety
Autism Spectrum Disorder
22Q11 Deletion
ADHD
Tic Disorders
Tourette Syndrome
ADHD Predominantly Inattentive Type
Neurodevelopmental Disorders

Interventions: Other: Placebo
Drug: Sertraline

First Posted Date: 2023-10-13

Last Posted Date: 2024-11-14

Lead Sponsor: Anagnostou, Evdokia, M.D.

Target Recruit Count: 130

Registration Number: NCT06081348

Locations: 🇨🇦
Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
🇨🇦
Alberta Children's Hospital - University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta-Glenrose, Edmonton, Alberta, Canada

and more 5 locations

Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome

Phase 3

Recruiting

Conditions: Burning Mouth Syndrome

Interventions: Drug: Duloxetine 60 MG
Drug: Vortioxetine 20Mg Tab
Drug: Escitalopram 10mg
Drug: Paroxetine 20 Mg Oral Tablet
Drug: Sertraline 50 MG
Drug: Citalopram 20mg
Drug: Pregabalin 75mg

First Posted Date: 2023-09-06

Last Posted Date: 2023-09-06

Lead Sponsor: Federico II University

Target Recruit Count: 203

Registration Number: NCT06025474

Locations: 🇮🇹
University of Naples Federico II, Napoli, Italia, Italy

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Phase 3

Recruiting

Conditions: Bipolar Depression

Interventions: Drug: Escitalopram
Drug: Sertraline
Drug: Venlafaxine
Drug: Lithium
Drug: Valproate acid
Drug: Quetiapine
Drug: Bupropion

First Posted Date: 2023-08-03

Last Posted Date: 2025-05-16

Lead Sponsor: Dr. Inge Winter

Target Recruit Count: 418

Registration Number: NCT05973786

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪
Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz, Mainz, Germany

and more 10 locations

Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Sertraline
Drug: Escitalopram

First Posted Date: 2023-07-18

Last Posted Date: 2023-07-18

Lead Sponsor: KRL Hospital, Islamabad

Target Recruit Count: 744

Registration Number: NCT05950061

Locations: 🇵🇰
KRL Hospital, Islamabad, Pakistan

Psychiatric Orders in Psychoanalytic Treatment of ASD

Active, not recruiting

Conditions: Panic Disorder With Agoraphobia, Severe Agoraphobic Avoidance and Mild Panic Attacks
Autism Spectrum Disorder High-Functioning
Depression, Reactive
Depression; Psychoneurotic
PTSD
OCD
Agoraphobia With Panic Attacks
Depression, Anxiety
Separation Insecurity
Depression, Unipolar